Cargando…

2732. Peri-Operative Antibiotic Management for Lung Transplant Recipients with Cystic Fibrosis

BACKGROUND: Lung transplant (LTx) recipients universally receive peri- and post-transplant antibiotics. Approaches to antibiotics for candidates with cystic fibrosis (CF) are institution specific. Little has been published about these practices. Routine LTx perioperative prophylaxis at our instituti...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, Melissa, Nichols, Courtney, Marschalk, Nicholas, Sarwar, Sajed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677707/
http://dx.doi.org/10.1093/ofid/ofad500.2343
_version_ 1785150193768857600
author Gordon, Melissa
Nichols, Courtney
Marschalk, Nicholas
Sarwar, Sajed
author_facet Gordon, Melissa
Nichols, Courtney
Marschalk, Nicholas
Sarwar, Sajed
author_sort Gordon, Melissa
collection PubMed
description BACKGROUND: Lung transplant (LTx) recipients universally receive peri- and post-transplant antibiotics. Approaches to antibiotics for candidates with cystic fibrosis (CF) are institution specific. Little has been published about these practices. Routine LTx perioperative prophylaxis at our institution is 96 hours of vancomycin and cefepime with antibiotics then adjusted for positive intraoperative donor and recipient cultures. In recipients with CF, perioperative prophylaxis is determined pre-LTx to cover colonizing organisms isolated in culture from the 2 years before LTx, adjusted for intraoperative cultures, and administered for 14-21 days post-LTx. Our study aims to add to the current literature by describing our center’s experience with antibiotic management and outcomes in lung transplant recipients with CF to help guide best practices for prophylaxis strategies for this patient population. METHODS: We performed a retrospective chart review of patients with CF who underwent LTx from 3/1/2015-11/18/21 at our center and were colonized pre-LTx with MRSA, Pseudomonas aeruginosa, or Burkholderia cepacia complex. Peri- and post-operative antibiotic regimens, donor and recipient culture results, changes in antibiotic therapy post-LTx, and duration of antibiotic therapy were documented. Outcomes included rehospitalization, isolation in culture of the prophylaxis-targeted organisms post-LTx, and mortality, within 6 months of LTx. RESULTS: Nineteen incidents of LTx were included in this study. Pre-LTx colonizing organisms and antibiotics administered are outlined in table 1. Prophylaxis-targeted organisms were infrequently isolated in culture after LTx (table 2), with 7/19 (36.8%) developing post-transplant infection with prior colonizing organisms. Four (21.1%) recipients developed post-LTx Clostridioides difficile infection. One (5.3%) recipient died within 6 months post-LTx. [Figure: see text] [Figure: see text] CONCLUSION: LTx recipients with CF who received targeted perioperative prophylaxis for pre-LTx colonizing organisms infrequently developed post-LTx culture positivity with the same bacteria including none during the antimicrobial prophylaxis period. Future prospective studies are needed to determine optimal antibiotic duration of peri-LTx antibiotics in this patient population. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-10677707
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106777072023-11-27 2732. Peri-Operative Antibiotic Management for Lung Transplant Recipients with Cystic Fibrosis Gordon, Melissa Nichols, Courtney Marschalk, Nicholas Sarwar, Sajed Open Forum Infect Dis Abstract BACKGROUND: Lung transplant (LTx) recipients universally receive peri- and post-transplant antibiotics. Approaches to antibiotics for candidates with cystic fibrosis (CF) are institution specific. Little has been published about these practices. Routine LTx perioperative prophylaxis at our institution is 96 hours of vancomycin and cefepime with antibiotics then adjusted for positive intraoperative donor and recipient cultures. In recipients with CF, perioperative prophylaxis is determined pre-LTx to cover colonizing organisms isolated in culture from the 2 years before LTx, adjusted for intraoperative cultures, and administered for 14-21 days post-LTx. Our study aims to add to the current literature by describing our center’s experience with antibiotic management and outcomes in lung transplant recipients with CF to help guide best practices for prophylaxis strategies for this patient population. METHODS: We performed a retrospective chart review of patients with CF who underwent LTx from 3/1/2015-11/18/21 at our center and were colonized pre-LTx with MRSA, Pseudomonas aeruginosa, or Burkholderia cepacia complex. Peri- and post-operative antibiotic regimens, donor and recipient culture results, changes in antibiotic therapy post-LTx, and duration of antibiotic therapy were documented. Outcomes included rehospitalization, isolation in culture of the prophylaxis-targeted organisms post-LTx, and mortality, within 6 months of LTx. RESULTS: Nineteen incidents of LTx were included in this study. Pre-LTx colonizing organisms and antibiotics administered are outlined in table 1. Prophylaxis-targeted organisms were infrequently isolated in culture after LTx (table 2), with 7/19 (36.8%) developing post-transplant infection with prior colonizing organisms. Four (21.1%) recipients developed post-LTx Clostridioides difficile infection. One (5.3%) recipient died within 6 months post-LTx. [Figure: see text] [Figure: see text] CONCLUSION: LTx recipients with CF who received targeted perioperative prophylaxis for pre-LTx colonizing organisms infrequently developed post-LTx culture positivity with the same bacteria including none during the antimicrobial prophylaxis period. Future prospective studies are needed to determine optimal antibiotic duration of peri-LTx antibiotics in this patient population. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10677707/ http://dx.doi.org/10.1093/ofid/ofad500.2343 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Gordon, Melissa
Nichols, Courtney
Marschalk, Nicholas
Sarwar, Sajed
2732. Peri-Operative Antibiotic Management for Lung Transplant Recipients with Cystic Fibrosis
title 2732. Peri-Operative Antibiotic Management for Lung Transplant Recipients with Cystic Fibrosis
title_full 2732. Peri-Operative Antibiotic Management for Lung Transplant Recipients with Cystic Fibrosis
title_fullStr 2732. Peri-Operative Antibiotic Management for Lung Transplant Recipients with Cystic Fibrosis
title_full_unstemmed 2732. Peri-Operative Antibiotic Management for Lung Transplant Recipients with Cystic Fibrosis
title_short 2732. Peri-Operative Antibiotic Management for Lung Transplant Recipients with Cystic Fibrosis
title_sort 2732. peri-operative antibiotic management for lung transplant recipients with cystic fibrosis
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677707/
http://dx.doi.org/10.1093/ofid/ofad500.2343
work_keys_str_mv AT gordonmelissa 2732perioperativeantibioticmanagementforlungtransplantrecipientswithcysticfibrosis
AT nicholscourtney 2732perioperativeantibioticmanagementforlungtransplantrecipientswithcysticfibrosis
AT marschalknicholas 2732perioperativeantibioticmanagementforlungtransplantrecipientswithcysticfibrosis
AT sarwarsajed 2732perioperativeantibioticmanagementforlungtransplantrecipientswithcysticfibrosis